Table 2.

Characteristics of men in PCBaSe 4.1 diagnosed with prostate cancer between 2014 by T2DM status

	No T2DM1, N = 27,229		T2DM, N = 4186
	N	%	N	%
T-stage,n(%)
T1a	642	2.4	146	3.5
T1b	331	1.2	90	2.2
T1c	13,288	48.8	1640	39.2
T2	7999	29.4	1328	31.7
T3	3593	13.2	713	17.0
T4	617	2.3	120	2.9
T0, Tx, Missing	759	2.8	149	3.6
N-stage,n(%)
N0	9112	33.5	1355	32.4
N1	1346	4.9	223	5.3
Nx, Missing	16,771	61.6	2608	62.3
M-stage,n(%)
M0	24,781	91.0	3690	88.2
M1	2423	8.9	493	11.8
Missing	25	0.1	3	0.1
PSA,n(%)
PSA < 4	3526	12.9	388	9.3
4 ≤ PSA < 10	12,373	45.4	1613	38.5
10 ≤ PSA < 20	4750	17.4	874	20.9
20 ≤ PSA < 50	2945	10.8	555	13.3
50 ≤ PSA < 100	1143	4.2	263	6.3
PSA ≥ 100	2492	9.2	493	11.8
Gleason Grade Group2,n(%)
Grade group 1	10,152	37.3	1152	27.5
Grade group 2	7183	26.4	1056	25.2
Grade group 3	3496	12.8	645	15.4
Grade group 4	2397	8.8	470	11.2
Grade group 5	3253	11.9	715	17.1
Missing	748	2.7	148	3.5

Numbers may not add up to 100% due to rounding

² Gleason grade group 1 = Gleason Score ≤ 6, Grade group 2 = Gleason Score 3 + 4 = 7, Grade group 3 = Gleason Score 4 + 3 = 7, Grade group 4 = Gleason Score 4 + 4, 3 + 5, 5 + 3 = 8, Grade group 5 = Gleason Score 9 and 10

Abbreviations: N number, T2DM type 2 diabetes mellitus, PSA Prostate-Specific Antigen